Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07032727 · ClinicalTrials.gov registry record · Phase 2
Olutasidenib Combined With Co-targeted Therapy in Relapsed or Refractory IDH1-mutated Myeloid Malignancies Harboring Activated Signaling Pathway Mutations
A Phase 2 study of Targeted Therapy and IDH1-Mutated Malignancies, sponsored by M.D. Anderson Cancer Center.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 68
- Enrollment target
- 1
- Study location
NCT07032727 is a Phase 2 study of Targeted Therapy and IDH1-Mutated Malignancies that is actively recruiting participants, run by M.D. Anderson Cancer Center. The registered enrollment target is 68 participants. The trial reports 1 study location across 1 state.
The verdict
NCT07032727, a Phase 2 study of Targeted Therapy and IDH1-Mutated Malignancies, is actively recruiting participants, sponsored by M.D. Anderson Cancer Center.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 68 participants
- Enrollment target
- 1
- Study location
Study Summary
To learn about the safety and tolerability of study drug combinations in patients with relapsed/refractory, IDH1-mutated myeloid malignancies with a co-signaling mutation.
Conditions Studied
Interventions
- DRUG Venetoclax
- DRUG Ruxolitinib
- DRUG Olutasidenib
- DRUG Gilteritinib
- DRUG Cladribine (CLAD)
Study Locations (1)
Texas
- MD Anderson Cancer Center - Houston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 68 participants |
| Start Date | 2025-09-12 |
| Est. Completion | 2029-06-01 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07032727
The ClinicalTrials.gov registry entry for NCT07032727 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 68 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is M.D. Anderson Cancer Center, which has 2,692 total studies on file at ClinicalTrials.gov.
The record links to 3 conditions, with Targeted Therapy appearing as the primary indexed condition, and to 5 interventions - of which Venetoclax is the first listed.
NCT07032727 reports 1 study location spanning 1 distinct geographic area - top geographies include Texas.
Frequently Asked Questions
What is clinical trial NCT07032727 about?
NCT07032727 is a clinical study titled "Olutasidenib Combined With Co-targeted Therapy in Relapsed or Refractory IDH1-mutated Myeloid Malignancies Harboring Activated Signaling Pathway Mutations". To learn about the safety and tolerability of study drug combinations in patients with relapsed/refractory, IDH1-mutated myeloid malignancies with a co-signaling mutation.
What is the current status of trial NCT07032727?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 68 participants. The study started on 2025-09-12. Estimated completion is 2029-06-01.
What conditions does trial NCT07032727 study?
This clinical trial studies the following conditions: Targeted Therapy, IDH1-Mutated Malignancies, Mutations.
What interventions are being tested in trial NCT07032727?
The interventions under investigation include: Venetoclax (DRUG), Ruxolitinib (DRUG), Olutasidenib (DRUG), Gilteritinib (DRUG), Cladribine (CLAD) (DRUG).
Who is sponsoring clinical trial NCT07032727?
This trial is sponsored by M.D. Anderson Cancer Center, which has 2,692 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07032727 being conducted?
This trial has 1 study location across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Targeted Therapy
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.